Compare Johnson Controls International PLC (JCI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Johnson Controls International PLC trades at $154.56 (market cap $93.28B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Johnson Controls International PLC pays a 1.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| JCI | VRTX | |
|---|---|---|
Market Cap | $93.28B | $127.55B |
Volume | 2,786,476 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $557.96 |
52-Week Low | $105.55 | $407.37 |
Typical Hold Time | 65 Days | 120 Days |
Enterprise Value | $102.12B | $121.68B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JCI trades at $155.93, down 1.78% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by 10% organic sales growth and a record $21 billion backlog. Profitability remains solid with a 14.32% net income margin and 24.42% ROE.
The stock offers upside to the $172.50 consensus price target, supported by strong fundamentals and institutional accumulation. Risks include elevated valuation multiples (P/E 43.38) and potential macroeconomic pressures on industrial demand. Continued execution on data center and building systems growth is key for sustained momentum.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
